Latest revenue
$24.3M
as of 2026-02-28
Latest net income
$4.5M
as of 2026-02-28
Net margin
18.7%
as of 2026-02-28
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $310.6M
- Enterprise value
- $310.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $34.01
- 52-wk low
- $11.09
- Beta
- —
- Shares out
- 20.2M
5-year trend
What this company does
ITEM 1 –BUSINESS As used in this Report, each of the terms “we,” “us,” “our,” the “Company,” and “Simulations Plus” refers to Simulations Plus, Inc. and its wholly owned subsidiaries (both current and previous, as applicable). Simulations Plus, Inc. was incorporated in California on July 17, 1996. The Company is a global leader and premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery and development, clinical trial operations, and commercialization. The Company supports its clients across the drug development lifecycle from early discovery through all phases of clinical research and development (“R&D”), including clinical…
AI summary unavailable — showing raw filing excerpt
Generated from SLP's filing dated 2025-12-01
Key risks
Table of Contents ITEM 1A – RISK FACTORS You should carefully consider the risks described below, as well as the other information in this Annual Report, including our financial statements and the related notes and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before investing in our securities. The occurrence of any of the events or developments described below could harm our business, financial condition, operating results, and/or growth prospects. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as competition, technological…
AI summary unavailable — showing raw filing excerpt
Generated from SLP's filing dated 2025-12-01
Profitability
Gross margin
58.4%
5.3%Operating margin
-89.3%
1120.1%Net margin
-81.7%
674.9%Return on equity
-51.9%
985.8%Return on assets
-49.1%
1069.0%Leverage
Debt / equity
0.06×
63.5%Debt / assets
5.4%
60.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-02-28 | $24.3M | +8.3% | $4.5M | +47.5% | 18.7% |
Q4 2025 2025-11-30 | $18.4M | -2.7% | $676.0K | +228.2% | 3.7% |
Q3 2025 2025-08-31 | $17.5M | -6.5% | $-4.0M | -569.9% | -22.7% |
Q2 2025 2025-05-31 | $20.4M | +9.8% | $-64.0M | -2141.3% | -314.5% |
Q1 2025 2025-02-28 | $22.4M | +22.5% | $3.1M | -23.7% | 13.7% |
Q4 2024 2024-11-30 | $18.9M | +30.5% | $206.0K | -89.4% | 1.1% |
Q3 2024 2024-08-31 | $18.7M | — | $843.0K | — | 4.5% |
Q2 2024 2024-05-31 | $18.5M | +14.2% | $3.1M | -21.7% | 16.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Computer Integrated Systems Design · SIC 7373
Your notes
Keep private notes on SLP — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$1.5M
Net activity
−$1.5M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns SLP
No institutional holdings on file for SLP yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once SLP's latest filing finishes processing.